Cantor Fitzgerald Thinks Tabula Rasa HealthCare’s Stock is Going to Recover

In a report released today, Steven Halper from Cantor Fitzgerald reiterated a Buy rating on Tabula Rasa HealthCare (TRHC), with a price target of $99. The company’s shares closed on Friday at $46.79, close to its 52-week low of $43.31.

Halper wrote:

“. We reiterate our Overweight rating on TRHC shares and maintain our 12-month price target at $99. Rasa reported 1Q19 results, which appeared to be strong. We note that the company posted strong organic growth of 19%. Adjusted EBITDA was above our estimate and the company reaffirmed its 2019 guidance for revenue and adjusted EBITDA. Our EPS estimates moved lower to reflect the higher interest expense given the 1Q19 convert. While the company has executed in the short term, we suspect that investors are more concerned about the number of acquisitions the company has completed in the last two years and its integration efforts.”

According to, Halper is a 5-star analyst with an average return of 16.4% and a 62.1% success rate. Halper covers the Services sector, focusing on stocks such as WellCare Health Plans, Tivity Health Inc, and Hms Holdings Corp.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tabula Rasa HealthCare with a $83.86 average price target, representing a 79.2% upside. In a report issued on May 9, Oppenheimer also assigned a Buy rating to the stock with a $88 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $91.16 and a one-year low of $43.31. Currently, Tabula Rasa HealthCare has an average volume of 400.8K.

Based on the recent corporate insider activity of 85 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Tabula Rasa Healthcare, Inc. engages in the development of pharmaceutical software that optimizes medication regimens. It offers cloud-based applications, such as EireneRx and MedWise Advisor. The company was founded by Calvin H. Knowlton and Orsula V. Knowlton in April 2009 and is headquartered in Moorestown, NJ.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts